作为负责人主持吴阶平基金1项(免疫治疗联合化疗对非鳞状细胞非小细胞肺癌脑转移患者一线治疗的有效性和安全性研究及生物标志物初探)
作为第一参与人参与国家自然科学基金(HDGF介导CAFs促进NSCLC肿瘤干细胞维持在化疗耐药中的功能和机制研究)
部分著作：
1、First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET. Journal of Nuclear Medicine, 2021:jnumed.121.262045（PET-CT在非小细胞肺癌中免疫治疗预测作用）
2、ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences.Crit Rev Oncol Hematol. 2022 Dec;180:103847（ALK抑制剂在ALK脑转移治疗现状及进展）
3、The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. Front. Oncol. 11:690093.（非小细胞肺癌免疫治疗预测指标探索）
4、Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study. Front. Mol. Biosci. 8:639892.（EGFR突变晚期非小细胞肺癌奥希替尼耐药后处理）
5、The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma, Clinical Cancer Research,2020.2（大细胞神经内分泌癌分子分型及治疗）
6、Optimal first-line treatment for advanced thymic carcinoma, Thoracic Cancer.2019.10.（胸腺癌一线治疗优选）
7、Simultaneous tongue metastasis from malignant pleural mesothelioma: Case report and literature review. Thoracic Cancer.2020.12.（间皮瘤舌转移的诊治）
8、1例EGFR突变晚期非小细胞肺癌患者靶向治疗策略探讨.中国肿瘤临床, 2021, 48(10).
9、非小细胞肺癌免疫治疗生物标志物的研究进展. 中国肺癌杂志, 2021, 24(11):7.
10、NSCLC携带EGFR少见突变分析及EGFR-TKIs疗效初步观察，中国肺癌杂志, 2015.8, 18(08):493~499.
11、 EGFR外显子20插入突变阳性NSCLC治疗的临床研究进展. 中国肺癌杂志, 2022, 25(5):337-350.
12、非小细胞肺癌的个体化治疗进展.中国肺癌杂志.2022.
